Nasdaq
$80.90▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.44BShares out 54.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 9.16After-hours26.09.17 05:234Ownership#●●●#●●●
LivaNova PLC
LivaNova PLC executive Anne M. Liddy reported a change in beneficial ownership of company securities effective September 15, 2026. This filing serves as a Form 4 statement disclosing the insider's updated share holdings.…more
$80.90+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14After-hours26.09.15 05:234Ownership
LivaNova PLC
LivaNova PLC insider Francesco Bianchi filed a Form 4 on September 14, 2026, reporting a change in beneficial ownership of securities as of September 10, 2026. This filing serves as an official record of the executive's equity position change.…more
$80.90+0.00%vs prev closeView filingShare - 9.10After-hours26.09.11 05:27144Ownership
LivaNova PLC
Francesco Bianchi, an executive at LivaNova PLC, has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard filing disclosing an executive's plan to dispose of their holdings.…more
$80.90+0.00%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoPre-market26.10.23 22:06#●●●#●●●
LivaNova Publishes 36-Month Results for VNS Therapy in Drug-Resistant Epilepsy…more
LivaNova has published the full 36-month results of its CORE-VNS study in the journal Neuromodulation. The study provides extensive data on the long-term effectiveness of VNS Therapy devices for patients with drug-resistant epilepsy.…more
$80.90+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga